Retrospective Clinical Research Report

Neutrophil/lymphocyte ratio is correlated with levels of inflammatory markers and is significantly reduced by smoking cessation

Maki Komiyama¹, Yuka Ozaki¹, Yusuke Miyazaki¹,², Yasufumi Katanasaka¹,², Yoichi Sunagawa¹,², Masafumi Funamoto¹,², Kana Shimizu¹,², Hajime Yamakage¹, Noriko Sato-Asahara¹, Akihiro Yasoda¹, Hiromichi Wada¹, Tatsuya Morimoto¹,² and Koji Hasegawa¹,²

Abstract

Previous studies have reported that the neutrophil to lymphocyte ratio (NLR) is associated with onset and prognosis of cardiovascular disease (CVD). Smoking is a major risk factor for CVD and smoking cessation significantly reduces CVD risk. However, the effects of smoking cessation on the NLR remain unknown. Among smokers visiting our smoking cessation clinics, we examined changes in the NLR and CVD biomarkers before and after smoking cessation. A total of 389 individuals (301 men and 88 women) were enrolled in the study. The median NLR was significantly reduced after successful smoking cessation (before: 1.8, interquartile range [IQR] 1.5, 2.5; after: 1.7, IQR 1.3, 2.4). In a linear regression model adjusted for sex, percent change in NLR comparing before and after smoking cessation was significantly and positively correlated with percent changes in C-reactive protein ($\beta = 0.260$), $\alpha$1-antitrypsin-low density lipoprotein ($\beta = 0.151$, $p < 0.05$), and serum amyloid A-low density lipoprotein ($\beta = 0.325$). Our study demonstrated for the first time that smoking cessation significantly reduces the NLR in tandem with markers of inflammation and oxidative stress.

¹Clinical Research Institute, National Hospital Organization Kyoto Medical Center, Kyoto, Japan
²Division of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan

Corresponding author:
Maki Komiyama, Chief Investigator, Clinical Research Institute, National Hospital Organization Kyoto Medical Center, 1-1 Mukaihata-cho, Fukakusa, Fushimi-ku, Kyoto 612-8555, Japan.
Email: nikonikomakirin@yahoo.co.jp

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Introduction

Increased neutrophil count is a marker of inflammation, while decreased lymphocyte count is a marker that reflects stress and poor nutritional condition. Several recent studies have reported that the ratio of neutrophil count the lymphocyte count (neutrophil/lymphocyte ratio, NLR) is associated with the onset of cardiovascular disease (CVD) and with prognosis of cancers.\(^1\)--4\) It has also been reported that NLR is a sensitive inflammatory marker of hypertension, dyslipidemia, diabetes mellitus, and obesity/metabolic syndrome, which are risk factors for arteriosclerosis.\(^5\)--8\) Inflammation attributable to smoking may destabilize atherosclerotic plaques and play roles in the onset of CVDs such as cerebral infarction and myocardial infarction.

Even in the absence of elevated C-reactive protein (CRP) levels, smokers have increased neutrophil counts.\(^9\) The detailed mechanisms through which smoking contributes to an increase in neutrophil count remain unknown. Cigarette smoke contains more than 250 hazardous substances, including 69 carcinogens; biological reactions to these substances result in increased neutrophil counts.\(^10\) The abundant neutrophils adhere to capillaries, increasing vascular resistance, and produce inflammatory cytokines that induce vascular injury and promote chronic inflammatory conditions in the arterial wall.\(^11,12\)

Despite normal leukocyte counts, an increase in the NLR increases risk for arteriosclerotic CVDs.\(^13,14\) Because the NLR could be predictive of CVD development, greater importance has been attached to leukocyte fractions in recent years.\(^13,15\) Multiple reports have demonstrated that the NLR is significantly higher in smokers than in non-smokers.\(^16,17\) However, the impact of smoking cessation on the NLR has not been clarified. In the present study, we investigated the effects of smoking cessation on leukocyte fractions.

Methods

Participants

Participants were smokers reporting for the first time to a smoking cessation outpatient clinic at the National Hospital Organization Kyoto Medical Centre. Patients with advanced cancer requiring palliative care were excluded. All smokers who fulfilled these criteria were asked to participate in the study. Those who provided written informed consent were included. Cardiovascular markers were measured in these subjects by collecting blood. In addition, medical history and information on smoking behavior was obtained through an interview at the initial visit to our smoking cessation clinic. At this time, body measurements were taken and blood tests were performed.

The present study was conducted in accordance with the principles laid out in the World Medical Association Declaration of Helsinki (revised October
Measurements

At the first visit to our department, information on participant age, sex, average cigarette consumption (number of cigarettes), duration of smoking, Fagerström Test for Nicotine Dependence (FTND) score, and current medications was obtained. The FTND is a standard test used to assess physical dependence on nicotine. The scores ranged from 0 to 10, with higher scores indicating more severe nicotine dependence. The number of cigarettes smoked per day was determined by asking the smoker the following question: “On average, in the past month, how many cigarettes did you smoke per day?”

Body measurements and blood tests were carried out at the start of smoking cessation therapy (0 months, baseline) and at the end of smoking cessation therapy (3 months after the start of therapy). Body measurements included height, weight, body mass index (BMI) abdominal circumference, blood pressure, and exhaled carbon monoxide (CO) concentration. Blood tests included hemoglobin A1C (HbA1c), low density lipoprotein (LDL)-C, high density lipoprotein (HDL)-C, neutral fat level, uric acid level, creatinine level, C-reactive protein (CRP), leukocyte count, neutrophil count, lymphocyte count, monocyte count, eosinophil count, and basophil count. In addition, levels of serum amyloid A-LDL (SAA-LDL), an oxidized form of LDL, and α1-antitrypsin-LDL (AT-LDL) were determined.

Statistical analysis

The Shapiro–Wilk normality test was conducted for individual test items. Normally distributed variables were expressed as means ± standard deviations (SDs); differences before and after smoking cessation were assessed using the paired t-test. Non-normally distributed variables were expressed as medians (interquartile ranges [IQRs]); differences before and after smoking cessation were assessed using the Wilcoxon signed-rank test.

Linear regression analysis adjusted for sex was carried out to assess correlations between NLR and the other variables before smoking cessation. In addition, correlations between change in NLR following smoking cessation and changes in other variables were assessed. Values of \( p < 0.05 \) were considered statistically significant.

Results

A total of 615 outpatients visiting our smoking cessation department for the first time provided written informed consent, and successfully gave up smoking through a 3-month course of smoking cessation therapy. Among these 615 individuals, leukocyte fraction data before and after smoking cessation were available for 389 (301 men and 88 women). These individuals were included in the analysis.

The mean (± SD) age of included smokers was 61.4 ± 11.8 years, the mean number of cigarettes smoked per day was 22.0 ± 10.4, the mean duration of smoking was
39.8 ± 11.5 years, and the mean FTND score was 6.4 ± 2.2 points.

A linear regression analysis adjusted for sex was used to assess correlation between NLR and other variables before smoking cessation therapy. Significant positive correlations were observed between NLR and CRP ($\beta = 0.402$, $p < 0.001$) and between NLR and SAA-LDL ($\beta = 0.162$, $p = 0.006$). Significant negative correlations were observed between NLR and systolic blood pressure ($\beta = -0.114$, $p = 0.029$) and between NLR and diastolic blood pressure ($\beta = -0.110$, $p = 0.039$) (Table 1).

Changes in parameters before and after smoking cessation therapy were investigated. BMI, abdominal circumference, LDL-C, HDL-C, neutral fat, uric acid, and creatinine showed significant increases post-therapy compared with baseline. Systolic blood pressure, diastolic blood pressure, leukocyte count, AT-LDL, and exhaled CO concentration showed significant decreases post-therapy compared with baseline. Among leukocyte fractions, neutrophils count were significantly lower and eosinophil count were significantly higher post-therapy compared with baseline. There were no significant changes in monocyte or basophil counts pre- and post-therapy. The NLR was significantly lower at the end of therapy compared with baseline (Table 2).

Linear regression analysis adjusted for sex was performed to assess correlations between changes in the NLR and changes

| Table 1. Sex-adjusted correlation coefficients between NLR and other clinical measurements at study baseline. |
|------|-------|-------|-------|-------|
|      | B     | SE    | $\beta$ | t    | p-value |
| Age  | 0.006 | 0.006 | 0.051  | 0.988 | 0.324   |
| Smoking amount | 0.003 | 0.007 | 0.024  | 0.468 | 0.640   |
| Smoking duration | 0.006 | 0.007 | 0.050  | 0.940 | 0.348   |
| Brinkman index   | 0.000 | 0.000 | 0.051  | 0.970 | 0.333   |
| FTND score       | -0.030| 0.033 | -0.046 | -0.898| 0.370   |
| BMI              | -0.030| 0.019 | -0.081 | -1.541| 0.124   |
| WC               | -0.007| 0.006 | -0.068 | -1.224| 0.222   |
| SBP              | -0.008| 0.004 | -0.114 | -2.186| 0.029   |
| DBP              | -0.013| 0.006 | -0.110 | -2.072| 0.039   |
| HbA1c (NGSP)     | -0.077| 0.070 | -0.060 | -1.101| 0.272   |
| LDL-C            | 0.000 | 0.002 | 0.012  | 0.224 | 0.823   |
| HDL-C            | 0.001 | 0.004 | 0.018  | 0.321 | 0.748   |
| TG               | -0.001| 0.001 | -0.062 | -1.172| 0.242   |
| UA               | 0.026 | 0.060 | 0.027  | 0.437 | 0.663   |
| Cre              | 0.301 | 0.189 | 0.087  | 1.590 | 0.113   |
| CRP              | 0.427 | 0.078 | 0.402  | 5.488 | <0.001  |
| SAA-LDL          | 0.011 | 0.004 | 0.162  | 2.779 | 0.006   |
| AT-LDL           | 0.062 | 0.079 | 0.046  | 0.787 | 0.432   |
| CO               | -0.006| 0.008 | -0.040 | -0.774| 0.439   |

B: regression coefficient, $\beta$: normalized regression coefficient.
Brinkman index, smoking amount (cigarettes/day) × smoking duration (years); FTND score, Fagerström test for nicotine dependence; BMI, body mass index = weight (kg) / (height (m))²; WC, waist circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure; HbA1c, hemoglobin A1c; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglyceride; UA, uric acid; Cre, creatinine; CRP, C-reactive protein; SAA-LDL, serum amyloid A-low density lipoprotein; AT-LDL, α1-antitrypsin-low density lipoprotein; CO, carbon monoxide.
in other variables pre- and post-therapy. There was a significant positive correlation between change in NLR and changes in HbA1c ($\beta = 0.108$, $p = 0.046$), CRP ($\beta = 0.260$, $p = 0.001$, Figure 1a), SAA-LDL ($\beta = 0.325$, $p < 0.001$, Figure 1b), and AT-LDL ($\beta = 0.151$, $p = 0.01$, Figure 1c). There was a significant negative correlation between change in NLR and change in systolic blood pressure ($\beta = -0.172$, $p = 0.001$) (Table 3).

Discussion
A cross-sectional study conducted pre-smoking cessation therapy revealed a significant positive correlation between NLR and CRP and between NLR and SAA-LDL. A longitudinal study conducted before and after smoking cessation intervention showed a significant positive correlation changes in NLR and levels of CRP, AT-LDL, and SAA-LDL. AT-LDL is an

| Table 2. Clinical measurements before and after smoking cessation. |
|-------------------------|-------------------------|-------------------------|
|                         | Baseline                | 3 months                | p-value |
| WBCs ($\times 10^3$/mm$^3$) | 6700 (5500, 8050)       | 6300 (5300, 7500)       | <0.001 b |
| Neutrophils ($\times 10^3$/mm$^3$) | 3872 (3010, 4796)     | 3415 (2700, 4348)       | <0.001 b |
| Lymphocytes ($\times 10^3$/mm$^3$) | 1976 (1551, 2501)     | 1986 (1560, 2506)       | 0.192 b  |
| Monocytes ($\times 10^3$/mm$^3$) | 523.8 (408.7, 630.9)  | 516.0 (400.0, 638.3)    | 0.744 b  |
| Eosinophils ($\times 10^3$/mm$^3$) | 162.5 (94.8, 253.7)   | 172.5 (107.5, 295.0)    | 0.007 b  |
| Basophils ($\times 10^3$/mm$^3$) | 45.0 (30.9, 66.3)      | 47.0 (31.0, 64.9)       | 0.497 b  |
| Neutrophil/lymphocyte ratio | 1.8 (1.5, 2.5)         | 1.7 (1.3, 2.4)          | <0.001 b |
| RBCs ($\times 10^3$/mm$^3$) | 4.5 (4.1, 4.8)         | 4.4 (4.1, 4.7)          | <0.001 b |
| Hb (g/dL)                | 14.4 (13.3, 15.2)      | 13.8 (12.9, 14.8)       | <0.001 b |
| Ht (%)                   | 43.5 (40.3, 46.5)      | 42.2 (39.6, 45.1)       | <0.001 b |
| MCV (%)                  | 96.0 (93.7, 99.6)      | 95.6 (92.3, 98.9)       | <0.001 b |
| MCH (%)                  | 31.8 (30.7, 33.0)      | 31.3 (30.5, 32.7)       | <0.001 b |
| MCHC (%)                 | 33.0 (32.5, 33.5)      | 32.8 (32.3, 33.5)       | 0.039 b  |
| SAA-LDL (mg/dL)          | 23.1 (20.7, 25.3)      | 23.3 (21.0, 25.8)       | <0.001 b |
| WC (cm)                  | 86.3 ± 10.7            | 87.7 ± 10.7             | <0.001 a |
| SBP (mmHg)               | 131.1 ± 20.0           | 128.1 ± 18.9            | 0.001 a  |
| DBP (mmHg)               | 77.7 ± 12.1            | 76.7 ± 11.9             | 0.042 a  |
| HbA1c (NGSP%)            | 5.8 (5.5, 6.4)         | 5.8 (5.5, 6.5)          | <0.001 b |
| LDL-C (mg/dL)            | 111.3 ± 29.6           | 114.7 ± 31.5            | 0.009 a  |
| HDL-C (mg/dL)            | 54.0 (45.0, 68.0)      | 57.0 (46.0, 71.0)       | <0.001 b |
| TG (mg/dL)               | 137.5 (93.8, 208.3)    | 156.0 (102.8, 240.3)    | <0.001 b |
| UA (mg/dL)               | 5.6 (4.5, 6.4)         | 5.9 (4.8, 7.0)          | <0.001 b |
| Cre (mg/dL)              | 0.79 (0.69, 0.92)      | 0.81 (0.70, 0.93)       | <0.001 b |
| CRP (mg/dL)              | 0.07 (0.04, 0.19)      | 0.08 (0.04, 0.19)       | 0.879 b  |
| SAA-LDL (mg/dL)          | 8.5 (5.3, 14.7)        | 9.0 (5.5, 15.0)         | 0.949 b  |
| AT-LDL (mg/dL)           | 1.5 (1.2, 2.2)         | 1.5 (1.2, 2.1)          | 0.044 b  |
| CO (ppm)                 | 13.0 (9.0, 20.0)       | 2.0 (1.0, 3.0)          | <0.001 b |

a: mean ± standard deviation, paired t-test, b: median (interquartile range), Wilcoxon signed-rank test. Values of $p < 0.05$ are shown in bold font.

WBC, white blood cell; RBC, red blood cell; Hb, hemoglobin; Ht, hematocrit; MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; BMI, body mass index; WC, waist circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure; HbA1c, hemoglobin A1c; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglyceride; UA, uric acid; Cre, creatinine; CRP, C-reactive protein; SAA-LDL, serum amyloid A-low density lipoprotein; AT-LDL, α1-antitrypsin-low density lipoprotein; CO, carbon monoxide.
oxidized form of LDL found in human serum at sites of atherosclerotic lesions. Levels of AT-LDL in the blood reflect the activity of foam cells in atherosclerotic lesions. SAA binds to HDL. When reactive oxygen species from inflammatory cells are activated by inflammatory signals in blood vessels, they bind SAA to LDL to form a complex known as SAA-LDL. SAA-LDL is a marker that can potentially be used to predict and prevent the occurrence of coronary events. Based on the above findings, NLR was considered a sensitive marker that reflects reduction of oxidative stress upon smoking cessation. In addition, increased NLR has been suggested to be associated with risk of developing CVDs and a rapid drop in the NLR in tandem with oxidized LDL levels after smoking cessation is likely to indicate decreased risk of cardiovascular injury.

CRP is an inflammatory marker associated with risk of developing CVD. In the present study, NLR significantly decreased at the end of smoking cessation therapy compared with baseline, while CRP did not significantly decrease. NLR had superior diagnostic accuracy for Crohn's disease accompanied by chronic inflammation, while CRP had superior diagnostic accuracy for disease activity. Therefore, CRP and NLR are likely to behave differently depending on symptoms. Inflammatory cytokines such as interleukin (IL)-1β and IL-6 increase CRP levels. IL-1β elevates the NLR by increasing the neutrophil count and decreasing the lymphocyte count; by contrast, IL-6 does not elevate NLR because it increases both neutrophil and lymphocyte counts. In addition to IL-1β and IL-6, various cytokines are involved in the induction of inflammation. Differences in the effects of inflammatory cytokines are likely to be associated with the divergent behavior of CRP and NLR.

Because nicotine has an extremely strong vasoconstrictive effect, tonic peripheral vasoconstriction is observed in smokers. In the present study, a significant drop in blood pressure was observed after smoking cessation. Moreover, a significant negative correlation was observed between change in NLR and change in systolic blood pressure comparing pre- and post-therapy. Although the NLR reflects inflammation, peripheral vessels are dilated by inflammatory mediators themselves. Therefore, blood pressure
decreases could be minimal among participants whose NLR was greatly reduced. It was reported that NLR was significantly higher in hypertensive patients, and vasculitis causes arteriosclerosis gradually over long periods, leading to strong vascular resistance. Thus, it is necessary to assess the relationship change in NLR and change in blood pressure after smoking cessation over longer periods in future studies.

Serum LDL cholesterol levels increased after smoking cessation. This increase was attributable to an increase in body weight. In general, body weight increases peak 3 years after smoking cessation, and then gradually decline. Despite the increase in body weight, epidemiological evidence shows that the risk of CVDs decreases after smoking cessation. This decreased risk could result from decreased oxidative stress and inflammation following smoking cessation, resulting in decreased levels of oxidized LDL implicated in atherosclerotic CVDs. Similarly, we previously reported that despite a progressive increase in body weight from baseline to 3 months and 1 year after smoking cessation, oxidized LDL levels progressively decrease.

NLR can be evaluated only by measuring the leukocyte fraction, which can be accomplished in a relatively short time in many medical institutions. The present study revealed for the first time that NLR rapidly drops in a relatively short time (3 months) after smoking cessation. For this reason, NLR may serve as a marker to conveniently evaluate risk of CVD after smoking cessation.

Limitations
The present study had several limitations. First, it was a single-center study and the observation period was only 3 months after smoking cessation. A long-term observational study of NLR is warranted.

Table 3. Sex-adjusted correlation coefficients between percent change in NLR and other clinical measurements.

|        | B     | SE  | β       | t     | p-value |
|--------|-------|-----|---------|-------|---------|
| BMI    | -0.710| 0.540| -0.069  | -1.313| 0.190   |
| WC     | -0.511| 0.562| -0.051  | -0.910| 0.364   |
| SBP    | -0.617| 0.184| -0.172  | -3.350| 0.001   |
| DBP    | -0.285| 0.186| -0.080  | -1.533| 0.126   |
| HbA1c (NGSP) | 0.591| 0.295| **0.108**| 2.005| **0.046** |
| LDL-C  | -0.046| 0.102| -0.025  | -0.456| 0.648   |
| HDL-C  | -0.015| 0.127| -0.006  | -0.120| 0.905   |
| TG     | -0.027| 0.031| -0.046  | -0.877| 0.381   |
| UA     | -0.216| 0.174| -0.074  | -1.243| 0.215   |
| Cre    | -0.206| 0.187| -0.060  | -1.104| 0.270   |
| CRP    | 0.015 | 0.005| **0.260**| 3.283| **0.001** |
| SAA-LDL| 0.084| 0.014| **0.325**| 5.848| <0.001 |
| AT-LDL | 0.242| 0.093| **0.151**| 2.599| **0.010** |
| CO     | 0.108 | 0.088| 0.064   | 1.222 | 0.222   |

B: regression coefficient, β: normalized regression coefficient. Values of p < 0.05 are shown in bold font.

BMI, body mass index; WC, waist circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure; HbA1c, hemoglobin A1c; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglyceride; UA, uric acid; Cre, creatinine; CRP, C-reactive protein; SAA-LDL, serum amyloid A-low density lipoprotein; AT-LDL, α1-antitrypsin-low density lipoprotein; CO, carbon monoxide.
Second, we examined two types of oxidized LDLs, AT-LDL and SAA-LDL, that are well-characterized factors associated with CVDs. We demonstrated that the NLR decreased in tandem with AT-LDL and SAA-LDL. Further studies are required to verify whether the decrease in the NLR after smoking cessation is also associated with a reduction in cardiovascular events.

Conclusions
The present study showed that smoking cessation significantly decreases the NLR. NLR is associated with a wide variety of diseases including CVDs, and a decrease in NLR following smoking cessation is suggestive of decreased risk of CVD.

Acknowledgment
We thank Yuko Iida for technical assistance.

Declaration of conflicting interest
The authors declare that there is no conflict of interest.

Funding
The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by a Grant-in-Aid for Clinical Research from the National Hospital Organization and a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (19K20139). The funders played no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

ORCID iD
Yuka Ozaki https://orcid.org/0000-0001-5672-855X

References
1. Angkananard T, Anothaisintawee T, McEvoy M, et al. Neutrophil lymphocyte ratio and cardiovascular disease risk: A systematic review and meta-analysis. *Biomed Res Int* 2018; 2018: 2703518.
2. Abe T, Kato S, Tsuruta Y, et al. Neutrophil/lymphocyte ratio as a predictor of cardiovascular events in incident dialysis patients: A Japanese prospective cohort study. *Clin Exp Nephrol* 2015; 19: 718–724.
3. Yamanaka T, Matsumoto S, Teramukai S, et al. The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in advanced gastric cancer. *Oncology* 2015; 73: 215–220.
4. Templeton AJ, McNamara MG, Šeruga B, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: A systematic review and meta-analysis. *J Natl Cancer Inst* 2014; 106: dju124.
5. Nam SH, Kang SG and Song SW. The neutrophil-lymphocyte ratio is associated with coronary artery calcification in asymptomatic Korean males: A cross-sectional study. *Biomed Res Int* 2017; 2017: 1989417.
6. Balta S, Kurtoglu E, Kucuk U, et al. Neutrophil-lymphocyte ratio as an important assessment tool. *Expert Rev Cardiovasc Ther* 2014; 12: 537–538.
7. Karaman M, Balta S, Seyit Ahmet AY, et al. The comparative effects of valsartan and amlodipine on vWF levels and N/L ratio in patients with newly diagnosed hypertension. *Clin Exp Hypertens* 2013; 35: 516–522.
8. Balta S, Celik T, Mikhailidis DP, et al. The relation between atherosclerosis and the neutrophil-lymphocyte ratio. *Clin Appl Thromb Hemost* 2016; 22: 405–411.
9. Bridges AB, Hill A and Belch JJF. Cigarette smoking increases white blood cell aggregation in whole blood. *J R Soc Med* 1993; 86: 139–140.
10. World Hospital Organization. Tobacco fact sheet, http://www.who.int/news-room/factsheets/detail/tobacco (2020, accessed 20 April 2021).
11. Ayhan H, Kasapkarah A, Aslan AN, et al. Relationship of neutrophil-to-lymphocyte ratio with aortic stiffness in type 1 diabetes mellitus. *Can J Diabetes* 2015; 39: 317–321.
12. Döring Y, Drechsler M, Soehnlein O, et al. Neutrophils in atherosclerosis: From mice to man. *Arterioscler Thromb Vasc Biol* 2015; 35: 288–295.
13. Bhat T, Teli S, Rijal J, et al. Neutrophil to lymphocyte ratio and cardiovascular diseases: A review. *Expert Rev Cardiovasc Ther* 2013; 11: 55–59.

14. Horne BD, Anderson JL, John JM, et al. Which white blood cell subtypes predict increased cardiovascular risk? *J Am Coll Cardiol* 2005; 45: 1638–1643.

15. Yu X, Li X, Li Y, et al. Neutrophil-lymphocyte ratio is associated with arterial stiffness in postmenopausal women with osteoporosis. *Arch Gerontol Geriatr* 2015; 61: 76–80.

16. Tulgar YK, Cakar S, Tulgar S, et al. The effect of smoking on neutrophil/lymphocyte and platelet/lymphocyte ratio and platelet indices: a retrospective study. *Eur Rev Med Pharmacol Sci* 2016; 20: 3112–3118.

17. Gumus F, Solak I and Eryilmaz MA. The effects of smoking on neutrophil/lymphocyte, platelet/lymphocyte ratios. *Bratisl Med J* 2018; 119: 116–119.

18. Fagerström KO, Heatherton TF and Kozlowski LT. Nicotine addiction and its assessment. *Ear Nose Throat J* 1990; 69: 763–765.

19. Heatherton TF, Kozlowski LT, Frecker RC, et al. The Fagerström test for nicotine dependence: a revision of the Fagerström tolerance questionnaire. *Br J Addict* 1991; 86: 1119–1127.

20. Terry A and Rustin MD. Assessing nicotine dependence. *Am Fam Physician* 2000; 62: 579–584.

21. Mashiba S, Wada Y, Takeya M, et al. *In vivo* complex formation of oxidized alpha(1)-antitrypsin and LDL. *Atherosclerosis Thromb Vasc Biol* 2001; 21: 1801–1808.

22. Komiyama M, Wada H, Ura S, et al. The effects of weight gain after smoking cessation on atherogenic z1-antitrypsin-low-density lipoprotein. *Heart Vessels* 2015; 30: 734–739.

23. Ogasawara K, Mashiba S, Wada Y, et al. A serum amyloid A and LDL complex as a new prognostic marker in stable coronary artery disease. *Atherosclerosis* 2004; 174: 349–356.

24. Gao SQ, Huang LD, Dai RJ, et al. Neutrophil-lymphocyte ratio: A controversial marker in predicting Crohn’s disease severity. *Int J Clin Exp Pathol* 2015; 8: 14779–14785.

25. Black S, Kushner I and Samols D. C-reactive protein. *J Biol Chem* 2004; 279: 48487–48490.

26. Ulich TR, Del Castillo J, Keys M, et al. Kinetics and mechanisms of recombinant human interleukin-1 and tumor necrosis factor-alpha-induced changes in circulating numbers of neutrophils and lymphocytes. *J Immunol* 1987; 139: 3406–3415.

27. Ulich TR, Del Castillo J and Guo KZ. *In vivo* hematologic effects of recombinant interleukin-6 on hematopoiesis and circulating. *Blood* 1989; 73: 108–110.

28. Derya MA, Demir V and Ede H. Relationship between neutrophil to lymphocyte ratio and blood pressure variability in hypertensive and normotensive subjects. *Turk Kardiyol Dern Ars* 2015; 43: 18–24.

29. Komiyama M, Shimada S, Wada H, et al. Time-dependent changes of atherosclerotic LDL complexes after smoking cessation. *J Atheroscler Thromb* 2016; 23: 1270–1275.